Gupta is an electronics exporter currently residing in California. While his main investments are in IT enterprises in international markets, his strategies are for his remaining capital for speculation are twofold. First , he shorts developing companies where I see too much government support in the infant stages. Second, he seeks out new catalyst-pending well-funded (privately) companies with experienced executive staff.
Recent Articles By The Author
Why Spectrum Fell on Beleodaq Approval but Will Rocket on Melphalan Approval
Spectrum's Beleodaq for Non-Hodgkin's lymphoma received FDA approval on July 3, but the stock then fell 26%. The same thing won't happen with Melphalan because sales numbers are already established.
Why Toyota's Move to Fuel Cells Won't Affect Electric Vehicle Sales
Toyota is scrapping its electric vehicle line to go into fuel cells. Is this a step backwards? Not really.
Why Vertex Pharmaceuticals Will Likely Climb to New High
Vertex Pharmaceuticals is now within weeks, or even days, of announcing top-line results on its two phase 3 cystic fibrosis studies. The science, phase 2 data, and FDA approval history for cystic fibrosis all suggest that Vertex is about to explode higher.